[Lieyun Network (WeChat:ilieyun
) Beijing] Reported on November 16
Lieyun.com recently learned that Pregene, a developer of CAR-T immunotherapy, announced the completion of its RMB 140 million Series B financing round and the initiation of its IPO process on the Hong Kong Stock Exchange. The round was led by Haier Medical, with participation from HUAPONT LIFE SCIENCES, Hunan Health and Elderly Care Industry Investment Fund, and existing shareholder Cash Capital (Beijing) Investment Management Co., Ltd.
Li Hongjian, Chairman and CEO of Pregene, stated: “This round of financing will support the multiple new drug clinical trials currently underway at the company, rapidly enrich our product pipeline, and advance our international expansion—including in Europe and the United States—so as to bring our products to market as soon as possible and benefit cancer patients.”
A Haier Medical investment executive stated, “Pregene has been deeply engaged in the field of cell and gene therapy for many years. Its core team possesses extensive management and R&D experience, and the company has established product pipelines in hematologic malignancies, solid tumors, and autoimmune diseases, demonstrating significant synergy with Haier Medical’s comprehensive oncology treatment scenarios. We believe that under the leadership of its team, Pregene will achieve rapid development, continuously launch outstanding oncology therapeutics, and benefit a broad population of cancer patients.”
Chen Hongwu, Executive Partner of Cash Capital, which has led multiple rounds of investment in Pregene, stated that after years of development, Pregene has become a platform-based company in the field of biopharmaceuticals. Particularly in the areas of cell therapy and gene therapy, it possesses an advanced drug molecule design and screening platform, rapid clinical translation and advancement capabilities, and a regulatory affairs team of international caliber. The company’s management team demonstrates global vision and strong business acumen, capable of both introducing international products to the local market and collaborating with major domestic pharmaceutical companies for mutual benefit. Cash Capital is honored to have participated in multiple financing rounds of Pregene and looks forward to Pregene making even greater contributions to the cause of human health.
HUAPONT LIFE SCIENCES announced that the investment in Pregene Biopharma is based on the company’s future overall strategic development needs, as well as its optimistic outlook on the cell therapy sector and Pregene Biopharma’s future development prospects. This move represents another concrete step in HUAPONT LIFE SCIENCES’ focused implementation of its “Big Health” development strategy. Through this strategic investment in Pregene Biopharma, the company can not only expand its layout in the field of biological innovative drugs and cultivate new potential profit growth points, but also rapidly enhance its competitive advantage in the biological innovative drug market through complementary advantages and synergistic development.
According to the Tianyancha app, Shenzhen Pregene Biopharma Co., Ltd. was established in November 2012, with Zhang Jishuai serving as its legal representative.Pregene is a globally leading innovative drug R&D enterprise specializing in cell and gene therapies, with a product pipeline that includes multiple leading candidates such as TCR-T, CAR-T, and stem cell therapies. Currently, its BCMA CAR-T therapy has obtained the first clinical trial approval for a CAR-T cell drug in South China.
Furthermore, the Company is also submitting Investigational New Drug (IND) applications to the U.S. FDA for multiple products. In October 2020, Pregene, together with Guangzhou Lingsheng, signed an exclusive license agreement with Bone Therapeutics, a pharmaceutical company listed on the London Stock Exchange, securing the rights for the production, clinical development, and commercialization of its proprietary universal off-the-shelf osteoblast cell therapy platform drug, ALLOB®, in the Asia-Pacific region.